Mirtazapine

Generic Name
Mirtazapine
Brand Names
Remeron
Drug Type
Small Molecule
Chemical Formula
C17H19N3
CAS Number
85650-52-8
Unique Ingredient Identifier
A051Q2099Q
Background

Mirtazapine is a tetracyclic piperazino-azepine antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder. The effects of this drug may be observed as early ...

Indication

This drug is indicated for the treatment of major depressive disorder and its associated symptoms.
...

Associated Conditions
Cancer Pain, Depression, Fibromyalgia, Generalized Anxiety Disorder, Hot Flashes, Insomnia, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Persistent Depressive Disorder (Dysthymia), Post Operative Nausea and Vomiting (PONV), Poststroke depression, Sleep disorders and disturbances, Substance Abuse Disorders, Tension Headache
Associated Therapies
-
Clinical Trials
Related News

Study of Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Fibromyalgia Syndrome

Phase 2
Completed
Conditions
Fibromyalgia Syndrome
Interventions
Drug: placebo
Drug: mirtazapine
First Posted Date
2009-06-12
Last Posted Date
2012-07-25
Lead Sponsor
Mahidol University
Target Recruit Count
80
Registration Number
NCT00919295
Locations
🇹🇭

Siriraj Hospital, Mahidol University, Bangkoknoi, Bangkok, Thailand

Short-term Metabolic Effects of Mirtazapine in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: mirtazapine
First Posted Date
2009-04-09
Last Posted Date
2010-09-16
Lead Sponsor
Max-Planck-Institute of Psychiatry
Target Recruit Count
12
Registration Number
NCT00878540
Locations
🇩🇪

Max Planck Institue of Psychiatry, Munich, Germany

The Effects of Mirtazapine Versus Placebo on Alcohol Consumption in Male Alcohol High Consumers

Phase 2
Completed
Conditions
Alcohol Dependence
Interventions
Drug: mirtazapine
Drug: placebo
First Posted Date
2009-04-02
Last Posted Date
2009-04-02
Lead Sponsor
Sahlgrenska University Hospital, Sweden
Target Recruit Count
59
Registration Number
NCT00874003
Locations
🇸🇪

Addiction Biology Unit, Gothenburg, Sweden

Effect of Quetiapine XR on Sleep in Patients With Major Depression, as Compared With Mirtazapine

Phase 3
Completed
Conditions
Sleep
Interventions
Drug: mirtazapine
Drug: quetiapine
First Posted Date
2008-10-31
Last Posted Date
2011-04-19
Lead Sponsor
Technical University of Munich
Target Recruit Count
40
Registration Number
NCT00782405
Locations
🇩🇪

Sleep Disorders Center, Munich, Bavaria, Germany

Dose Response of Mirtazapine to Methamphetamine Induced Interest, Mood Elevation and Reward

Not Applicable
Withdrawn
Conditions
Amphetamine Dependence
Interventions
Other: Placebo
Drug: Mirtazapine
First Posted Date
2008-01-24
Last Posted Date
2011-04-27
Lead Sponsor
University of Virginia
Registration Number
NCT00600145
Locations
🇺🇸

Universiyt of Virginia, Charlottesville, Virginia, United States

Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors

First Posted Date
2007-07-06
Last Posted Date
2015-01-05
Lead Sponsor
San Francisco Department of Public Health
Target Recruit Count
60
Registration Number
NCT00497081
Locations
🇺🇸

San Francisco Department of Public Health, Substance Use Research Unit, San Francisco, California, United States

Effects of Mirtazapine on Appetite in Advanced Cancer Patients

Phase 2
Active, not recruiting
Conditions
Weight Loss
Advanced Cancer
Anorexia
Insomnia
Interventions
Drug: Mirtazapine
Drug: Placebo
First Posted Date
2007-06-19
Last Posted Date
2024-11-28
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
98
Registration Number
NCT00488072
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects

First Posted Date
2006-05-05
Last Posted Date
2017-04-20
Lead Sponsor
Boston University
Target Recruit Count
24
Registration Number
NCT00322309
Locations
🇺🇸

Boston University, Boston, Massachusetts, United States

A Placebo-Controlled Study of Mirtazapine for PTSD

Phase 4
Completed
Conditions
Anxiety
PTSD
Interventions
Drug: Mirtazapine
Drug: Placebo
First Posted Date
2006-03-13
Last Posted Date
2014-11-26
Lead Sponsor
US Department of Veterans Affairs
Target Recruit Count
78
Registration Number
NCT00302107
Locations
🇺🇸

Tuscaloosa VAMC, Tuscaloosa, Alabama, United States

PET Neuroimaging of [11C]Mirtazapine

First Posted Date
2006-02-08
Last Posted Date
2007-04-19
Lead Sponsor
University of Aarhus
Target Recruit Count
24
Registration Number
NCT00288782
Locations
🇩🇰

Center for Psychiatric Research, Psychiatric Hospital of Aarhus University, Risskov, Denmark

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy